We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
35 hedge funds and large institutions have $7.2M invested in Crescent Biopharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,434% more call options, than puts
Call options by funds: $675K | Put options by funds: $44K
0.18% less ownership
Funds ownership: 0.57% → 0.4% (-0.18%)
49% less funds holding
Funds holding: 69 → 35 (-34)
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
92% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 37
93% less capital invested
Capital invested by funds: $111M → $7.2M (-$103M)
Holders
35
Holders Change
-34
Holders Change %
-49.28%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
16
Closed
37
Calls
$675K
Puts
$44K
Net Calls
+$631K
Net Calls Change
-$823K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$712K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$212K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$140K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$84.7K |
| 5 |
Two Sigma Advisers
New York
|
+$82.7K |
Top Sellers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$11.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$9M |
| 3 |
Axa
Paris,
France
|
-$4.76M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$653K |
| 5 |
Millennium Management
New York
|
-$583K |
